alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionate receptor autoradiography in mouse brain after single and repeated withdrawal from diazepam.
Withdrawal from chronic treatment with benzodiazepines is associated with increased neuronal excitability leading to anxiety, aversive effects and increased seizure sensitivity. After repeated withdrawal experiences, seizure sensitivity increases while withdrawal-induced anxiety and aversion decrease. We used autoradiographical methods employing [(3)H]Ro48 8587, a selective ligand for glutamatergic alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptors, to study withdrawal-induced changes in AMPA receptor binding in areas of the mouse brain postulated to be involved in these responses. Mice were given 21 days treatment with diazepam (15 mg/kg, s.c. in sesame oil) followed by withdrawal (single withdrawal) or three blocks of 7 days treatment interspersed with 3-day periods to allow washout of drug (repeated withdrawal). In keeping with heightened excitability in withdrawal from chronic diazepam treatment, the single withdrawal group showed, 72 h after their final dose of diazepam, increased [(3)H]Ro48 8587 binding in several brain areas associated with emotional responses or seizure activity, including hippocampal subfields, amygdalar and thalamic nuclei and motor cortex. In contrast, the repeated withdrawal group showed no changes in [(3)H]Ro48 8587 binding in any brain area studied. These observations are consistent with up-regulation of AMPA receptor-mediated transmission being important in withdrawal-induced anxiety and aversion but not in increased seizure sensitivity associated with repeated withdrawal. As changes in AMPA receptor subunit expression alter the functionality of the receptor, future studies will address this possibility.
Allison
C
C
Department of Pharmacology and Physiology, University of Strathclyde, 27 Taylor Street, Glasgow G4 ONR, UK.
Pratt
J A
JA
Ripley
T L
TL
Stephens
D N
DN
D000818:Animals; D001345:Autoradiography / Q000379:methods; D001921:Brain / Q000033:anatomy & histology / Q000187:drug effects* / Q000378:metabolism; D001931:Brain Mapping; D003975:Diazepam / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D018757:GABA Modulators / Q000008:administration & dosage* / Q000009:adverse effects; D007093:Imidazoles / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011485:Protein Binding / Q000187:drug effects; D011799:Quinazolines / Q000494:pharmacology; D018091:Receptors, AMPA / Q000378:metabolism*; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology*; D013997:Time Factors; D014018:Tissue Distribution / Q000187:drug effects; D014316:Tritium / Q000494:pharmacology
D018757:GABA Modulators; D007093:Imidazoles; D011799:Quinazolines; D018091:Receptors, AMPA; C112933:Ro 48-8587; D014316:Tritium; D003975:Diazepam